Biosimilars have become an increasingly important part of modern healthcare, particularly as healthcare systems seek to expand access to advanced therapies while maintaining sustainable treatment pathways. Although often discussed alongside generic medicines, biosimilars follow a distinctly different development journey due to the complexity of the biological medicines they are designed to replicate. Understanding how biosimilars are developed provides valuable insight into the scientific, manufacturing, and regulatory processes that underpin these products.
Biologic medicines are produced using living cells and sophisticated biotechnology processes. Unlike traditional medicines, which are generally manufactured through defined chemical synthesis, biologics are large, complex molecules that are highly sensitive to manufacturing conditions. Small variations in production processes can influence the final product, which is why biosimilars cannot be exact copies in the same way that generic medicines are. Instead, they are developed to demonstrate a high degree of similarity to an already approved reference biologic.
The biosimilar development process begins with extensive analytical comparison. Scientists first study the reference product in detail, examining its structure, biological activity, purity profile, and functional characteristics. Advanced laboratory techniques are used to compare hundreds of molecular attributes, ensuring that the biosimilar closely matches the reference medicine. This analytical phase forms the foundation of biosimilar development and is often far more extensive than the testing required for conventional medicines.
Following laboratory analysis, developers conduct a series of comparative studies designed to confirm that any observed differences are not clinically meaningful. These studies may include preclinical evaluations, pharmacokinetic assessments, and targeted clinical trials. The objective is not to re-establish the efficacy of the original medicine, which has already been demonstrated, but rather to confirm that the biosimilar performs in a highly similar manner in terms of safety, efficacy, and quality.
Manufacturing plays a particularly important role in biosimilar development. Production typically involves specialised cell lines, controlled fermentation processes, purification systems, and stringent quality controls. Manufacturers must demonstrate that they can consistently produce the product to the required specifications across multiple production batches. This level of consistency is essential because biological products are inherently more complex than traditional small-molecule medicines.
Regulatory review of biosimilars reflects this complexity. Authorities such as SAHPRA, the European Medicines Agency (EMA), and other leading regulators assess comprehensive comparability packages that include analytical, non-clinical, and clinical data. The approval pathway is therefore built around demonstrating similarity to an established reference product rather than independently repeating the entire development process. This science-based approach enables regulatory authorities to evaluate biosimilars against internationally recognised standards while maintaining rigorous oversight.
Today, biosimilars are available across a growing number of therapeutic areas, including oncology, autoimmune diseases, diabetes, and supportive care treatments. As patents on originator biologics expire, biosimilars are expected to continue expanding treatment options and increasing healthcare system capacity to provide access to advanced therapies.
The journey from molecule to market demonstrates that biosimilar development is founded on innovation, scientific precision, and rigorous quality standards. While biosimilars may follow an abbreviated regulatory pathway compared with originator biologics, the level of evidence required to establish similarity remains extensive. Through advanced manufacturing, comprehensive analytical assessment, and robust regulatory oversight, biosimilars have become an established component of modern medicine and an increasingly important contributor to healthcare access around the world.